

- 1 Analysis of fatality among COVID-19 cases in Mexican pregnant women: a cross-sectional study
- 2 Short title: Fatality and COVID-19 in pregnancy
- 3 Nicolás Padilla-Raygoza<sup>\*1#a</sup>, María de Jesús Gallardo-Luna<sup>1</sup>, Gilberto Flores-Vargas<sup>1</sup>, Efrain Navarro-
- 4 Olivos<sup>2#b</sup>, Francisco J. Magos-Vázquez<sup>3#c</sup>, Elia Lara-Lona<sup>3#c</sup>, Daniel A. Díaz-Martínez<sup>3#c</sup>
- 5 <sup>1#a</sup> Department of Research and Technological Development, Directorate of Teaching and
- 6 Research, Institute of Public Health from Guanajuato State, Guanajuato, Gto., México
- 7 <sup>2#b</sup> Directorate of Teaching and Research, Institute of Public Health from Guanajuato State,
- 8 Guanajuato, Gto., Mexico
- 9 <sup>3#c</sup> Directorate of Health Services. Institute of Public Health from Guanajuato State, Guanajuato,
- 10 Gto., Mexico
- 11
- 12 Current Address:
- <sup>#a</sup> Department of Research and Technological Development, Víctor Cervera Pacheco #14 Primer
- 14 Piso, Plaza Santa Fé, Guanajuato, Gto., Mexico
- 15 Current Address:
- 16 <sup>#b</sup> Directorate of Teaching and Research, Víctor Cervera Pacheco #14 Primer Piso, Plaza Santa Fé,
- 17 Guanajuato, Gto., Mexico CP36250
- 18 Current Address:
- 19 <sup>#c</sup> Directorate of Health Services, Tamazuca #4, Guanajuato, Gto., Mexico CP36000
- 20
- 21 \* Corresponding Author
  - 1



22 E-mail: npadillar@guanajuato.gob.mx (NP-R)

# 23 Abstract

24	This study aims to analyze the fatality of cases confirmed by COVID-19 among
25	pregnant women in Mexico. It is a cross-sectional and analytical study. We used the
26	registries from pregnant women available in the open database of the National
27	Epidemiological Surveillance System from the General Directorate of Epidemiology. We
28	showed descriptive statistics for all the variables. A suspected case of COVID-19 is any
29	person who presented the following signs and symptoms: fever, headache, cough, and
30	others. A confirmed case is any suspected case with a positive RT- PCR test result. We
31	computed OR and 95% confidence intervals to estimate the effect of independent variables
32	on dying from COVID-19. Also, it was calculated the Case Fatality Ratio (CFR) among
33	pregnant women. The alpha value was fixed at 0.05 as a threshold to show statistical
34	significance. The CFR was 1.09%. For confirmed cases, the average age among those who
35	died was higher than among those who did not die (P < $0.05$ ). The average time between the
36	onset of symptoms and registration in the system was higher for those who died (P < $0.05$ ).
37	Among the deceased, 76.97% had pneumonia. For the 40-49 years age group, the effect on
38	death was statistically significant (OR 4.97, CI95% 1.77 – 17.85). Outpatient care had a
39	protective effect on dying (OR 0.04, CI95% 0.02 – 0.09). Pneumonia was highly associated
40	with death (OR 8.68, CI95% 5.72 – 13.6). Co-morbidities did not affect dying while
41	considering them in a multivariable logistic regression model. Among pregnant women,
42	smoking has little effect on death by COVID-19. The CFR was low compared with the rest
43	of the Mexican population. The co-morbidities had a low prevalence among pregnant



- 44 women. Since the reproductive age span is young age, pregnant women have two protective
- 45 factors for COVID-19 detected so far: being young and woman.
- 46 Keywords: SARS-CoV-2, COVID-19, Reproductive age, Fatality; Surveillance system,
- 47 Pregnancy

## 48 Introduction

In November-December 2019, several cases of pneumonia of unknown origin were 49 detected in Wuhan, China [1]. After genomic analyses, the pathogen responsible was 50 51 determined and called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Meanwhile, the disease was named Coronavirus Disease 2019 (COVID-19) [2]. Since then, 52 this disease has spread to the entire world. By November 1, 2021, 246,594,191 cases and 53 4.998.784 deaths have been reported in 224 countries [3]. 54 55 Pregnant women are likely to represent a high-risk population in the COVID-19 pandemic. Although pregnant women infected with SARS-CoV-2 are predominantly 56 asymptomatic or present mild COVID-19 -very similar to non-pregnant women [4]- they 57 may be at higher risk of severe COVID-19 than the general population, according to 58 Wastnedge et al. [5]. 59 In a report from seven pregnant women infected by SARS-CoV-2 in Wuhan, China, 60

In a report from seven pregnant women infected by SARS-CoV-2 in Wuhan, China,
all were in the last pregnancy trimester and had contact with the epidemic area, but not with
food from the seafood market in the same city. The median age was 32 years -spreading
between 29 and 34 years- and none was required to be treated in the ICU [6].

64 Pregnant women are considered a group at risk during the pandemic by SARS-CoV65 2 due to biological processes related to pregnancy. It is hypothesized that a shift in the CD4



66	+ cell population towards the Th2 phenotype, promoting the humor response, mediates the
67	altered inflammatory response to viruses during pregnancy. The Th2 and Th1 response has
68	been implicated in the pathogenesis of severe COVID-19 [7]. Also, during pregnancy, a
69	decrease in natural killer (NK) cells occurs [8], and the NKs participate in virus
70	neutralization [9]. The effect of the NK decreasing in the clinical picture of COVID-19 is
71	unknown. There are other immune effects as progesterone levels [10] and alterations in
72	Toll-like receptors (TLRs) [11]. It remains to be elucidated whether they have protective or
73	harmful effects on pregnant women with COVID-19 [5]. Besides, the reduction in total
74	lung capacity and the inability to expel secretions can make pregnant women more
75	susceptible to severe respiratory infections [12].
76	Pregnancy is also a hypercoagulable state, with increased thrombin production and
77	intravascular inflammation [13]. On the other hand, COVID-19 has been associated with
78	thromboembolic complications in 31% of the patients reported in Knight M et al. [14].
79	According to Lopez-Rodriguez et al. [15], in 29,416 pregnant Mexican women,
80	39% had a COVID-19-positive diagnosis. They found that the risk of death was three times
81	higher among those positive for COVID-19 than those who tested negative.
82	This paper aims to analyze the cases of COVID-19 in pregnant women registered in
83	the open and public database of the National Epidemiological Surveillance System (NESS)
84	from the General Directorate of Epidemiology (GDE) of the Ministry of Health (MH) [16]
05	

# 86 Material and methods



87 The study was approved by the Research Ethics Committee from the Salamanca88 General Hospital, Mexico.

### 89 2.1 Study design

90 It is a cross-sectional and analytical study.

As a requisite to be tested, pregnant women must meet the operational definition of suspected cases of respiratory viral infection (17). A suspected case of viral disease is considered as anyone who presents fever, headache, cough, or dyspnea (signs of severity), in addition to one of the following: myalgias, arthralgias, odynophagia, chills, chest pain, rhinorrhea, anosmia, dysgeusia, or conjunctivitis. If a subject meets the operational definition, the subject undergoes a nasopharyngeal Real-Time Polymerase Chain Reaction (RT-PCR) test (17).

The variables included in the database are the following: state of residence, age,
date of onset of symptoms, date of registration, date of death (if it occurred), hospital or
outpatient management, pneumonia diagnosis, underlying presence of diabetes, Chronic
Obstructive Pulmonary Disease (COPD), asthma, immunosuppression, hypertension,
cardiovascular disease, chronic kidney disease, obesity, or smoking. The diagnosis tool for
COVID-19 was the real-time polymerase chain reaction test (RT-PCR) (16, 17).

104 The database does not record gestational age at the time of positive diagnosis for105 SARS-CoV-2.

After the approval of the research protocol by the ethics committee for research, wedownloaded the open database of the NESS/GDE, and we preprocessed it to verify the data



consistency. The dataset was analyzed in STATA 13.0 ® (Stata Corp., College Station, TX,
USA). NESS/GDE database does not include personal data.

### 110 2.2 Statistical analysis

- 111 Descriptive statistics are presented for all the variables. To compare quantitative
- variables between confirmed COVID-19 cases, deceased or not, the Student t-test was
- 113 performed. To compare categorical variables, the Chi-squared was used. Odds Ratio (OR)
- and 95% confidence intervals (95%CI) were calculated to estimate the effect of
- independent variables on dying from COVID-19. Also, it was calculated the Case Fatality
- 116 Ratio (CFR) among pregnant women. In all cases, the corresponding P-values are present.
- 117 Also, to demonstrate the statistical significance of the results, the alpha value was set at
- 118 0.05. Statistical analysis was performed in STATA 13.0 ® (Stata Corp., College Station,

119 TX, USA).

120

## 121 **Results**

### 122 **Description of the pregnant women population**

- 123 In the NESS/GDE database, 42,334 pregnant women were reported; from them, 13,891
- 124 (32.81%) tested positive for SARS-CoV-2 and 28,443 (67.19%) tested negative (16).

### 125 Characterization of death cases

Both SARS-CoV-2 positive and negative pregnant women had an age range of 12 to 49 years and a mean of  $28.41 \pm 6.13$  years for the former and  $27.09 \pm 6.36$  years for the



128	latter -the difference was statistically significant ( $P = .00001$ ) According to the database,
129	the difference between the onset of symptoms and registry into the system, on average, is
130	higher among COVID-19 cases than among negative ones (P $<$ .05) (Table 1).
131	The CFR was 152/13,739 (1.1%). For confirmed cases, the average age among the
132	deceased cases was greater than among those who did not die (P <0.05). The average time
132 133	deceased cases was greater than among those who did not die (P <0.05). The average time between the onset of symptoms and registration into the system was greater among those

134 who died. (P <0.05) (Table 1).

#### 135 Table 1 Distribution of quantitative variables among deaths and non-deaths by

#### 136 COVID-19 in Mexican pregnant

	Confirmed CO		
Variable	Deaths	Non-deaths	t-test, df, <i>P-value</i>
	(n=152)	(n=13,739)	
Age (years)			
Minimum to maximum	16 to 49	12 to 49	6.42, 13889, <0.001
Mean ± S	$31.59\pm6.89$	$28.38\pm6.12$	
Time between beginning of symptoms and date of registry (days)			4.96, 13899, <0.001
Minimum to maximum	0 to 16	0 to 39	,,
Mean ± S	$4.90 \pm 3.55$	$3.68 \pm 3.06$	

- 137 **Abbreviations:** df degree of freedom
- 138

Between pregnant women positive for COVID-19, the CFR by age group were: 12-

140 19 years, 0.44%, 20-29 years, 0.78%, 30-39 years, 1.36%, and 40-49 years, 3.74%.

141 The predominant age group among the deceased cases was 30-39 years (47.37%).

Meanwhile, in the non-deceased, those aged 20 to 29 years (51.63%) (P < 0.05)

143 predominated.



### 144 Associated risk factors for lethality

- 145 Among the deceased cases, hospitalized patients predominated (93.42%). Compared
- 146 with the non-deceased, where most subjects received outpatient management (82.27%) (P
- 147 <0.05). Among the deceased, 76.97% had pneumonia. Among the non-deceased, only
- 148 17.73% had it (P < 0.05). A statistically significant relationship with death (P < 0.05) was
- 149 found for diabetes, COPD, asthma, immunosuppression, hypertension, chronic kidney
- 150 disease, obesity, and smoking (Table 2).

#### 151 Table 2 Relationship between variables and deaths by COVID-19 in Mexican

#### 152 pregnant women.

	Confirmed COVID-19 cases				
	Deaths		Non-deaths		X <sup>2</sup> , df, <i>P-value</i>
	n	%	n	%	
Age group (years)					
12 to 19	4	2.63	897	6.53	
20 to 29	56	36.84	7094	51.6	47.86, 3, <0.001
30 to 39	72	47.37	5233	38.1	
40 to 49	20	13.16	515	3.75	
Care type					
Hospitalized	142	93.42	2436	17.7	569.84, 1, <0.001
Ambulatory	10	6.58	11303	82.3	
Pneumonia					
Yes	117	76.97	952	6.93	1000.03, 1, <0.001
No	35	23.03	12787	93.1	
Diabetes					
Yes	20	13.16	414	3.01	74.04, 1, <0.001
No	130	85.53	13313	96.9	
Chronic Obstructive					
Pulmonary Disease					* 1 17 < 0.001
Yes	0	0	21	0.15	-4.17, <0.001
No	149	98.03	13706	99.8	
Asthma					
Yes	5	3.29	279	2.03	28.15, 1, <0.001
No	145	95.39	13450	97.9	
Immunosuppression					
Yes	2	1.32	91	0.66	17.70, 1, <0.001
No	148	97.37	13632	99.2	



Hypertension					
Yes	15	9.87	362	2.63	35.74, 1, <0.001
No	136	89.47	13366	97.3	
Cardiovascular Disease					
Yes	0	0	59	0.43	*-1.38, 0.17
No	150	98.68	13669	99.5	
Chronic Kidney Disease					
Yes	3	1.97	39	0.28	35.09, 1, <0.001
No	147	96.71	13687	99.6	
Obesity					
Yes	26	17.11	1026	7.47	29.76, 1, <0.001
No	125	82.24	12706	92.5	
Smoking					
Yes	2	1.32	262	1.91	27.27, 1, <0.001
No	148	97.37	13467	98	

153 Notes: \* Z for two proportions

154

Using the logistic regression model that included all the variables with a statistically 155 significant relationship with death, an effect on dying was detected for the age group from 156 157 40 to 49 years (OR 4.97 95%CI 1.77-17.85). The difference in days between the onset of symptoms and system registration is in the border area. The type of outpatient care has a 158 protective effect on dying (OR 0.04 95%CI 0.02-0.09). Meanwhile, Pneumonia shows a 159 high association (OR 8.68 95%CI 5.72-13.6). Diabetes, asthma, immunosuppression, 160 hypertension, chronic kidney disease, and obesity did not affect death. As seen in the 161 162 variance inflation factor (VIF), these variables may be highly correlated. Hence, they have little influence on the model. Smoking has little effect on death due to COVID-19 among 163 pregnant women (Table 3). We fitted a model by omitting diabetes, immunosuppression, 164 165 hypertension, and chronic kidney disease -those with higher VIF, different age groups, and 166 non-statistically significant effects-. The Bayesian Information Criteria decreased from 167 1217.52 in the original model to 1190.26. The likelihood ratio test showed a statistically



- significant difference between the models. Nevertheless, the qualitative results were the
- 169 same.
- 170 Table 3 Logistic regression model including all independent variables with death in
- 171 Mexican pregnant women

Deaths	OR	(95% CI) adjusted	VIF
Age group			
	Reference		
12-19	group		
20 – 29	1.67	(0.66 - 5.68)	8.97
30 – 39	2.34	(0.93 - 7.92)	9.39
40 – 49	4.97	(1.77 - 17.85)	4.55
Difference in days	1.04	(0.99 - 1.09)	1.02
Care type	0.04	(0.02 - 0.09)	1.27
Pneumonia	8.68	(5.72 - 13.6)	1.22
Diabetes	0.98	(0.89 - 1.04)	9.56
Chronic Obstructive Pulmonary Disease	1.07	(1.04 - 1.11)	2.66
Asthma	1.05	(1-1.1)	4.48
Immunosuppression	0.95	(0.84 - 1.03)	49.11
Hypertension	0.97	(0.87 - 1.02)	16.02
Chronic kidney disease	0.99	(0.87 - 1.06)	32.98
Obesity	0.96	(0.87 - 1.01)	1.68
Smoking	1.05	(1.01 - 1.09)	1.91

172 Notes: VIF Variance inflation factor

173

# 174 **Discussion**

175 The CFR reported by Padilla et al. [18] for the Mexican population on May 15,

176 2020 (10.59%) was higher than the one for the sample in this study (1.1%). Padilla et al.

177 [18] also mentions that 68.14% of the deaths were in males and 49.57% in those over 60

178 years.



Table 2 reports a relationship between the study variables and death from COVID19, except for cardiovascular disease. When quantifying the effect of these variables, only
the age group, the difference in days between the onset of symptoms and the registration in
the system, the type of care, pneumonia, COPD, asthma, and smoking affected death (Table
3).

Of nine pregnant women with COVID-19 and pneumonia, none developed severe 184 pneumonia or died, as reported by Cheng et al. [19]. In the sample of Mexican pregnant 185 186 women, 18.56% were hospitalized, 7.70% developed pneumonia, and 1.09% died (Table 2). In a series of 116 cases of pregnant women with COVID-19, 8% developed pneumonia 187 [20], like the results in this study. Yu et al. [21] reported 124 maternal deaths in Brazil 188 189 between February and June 2020. At the same time, Mexico reported seven maternal deaths [22]. The increase in maternal mortality from COVID-19 in Brazil may be due to a 190 191 decreased availability of health professionals or a lack of intensive care units. 192 There is no evidence that pregnant women are more susceptible to SARS-CoV-2

193 [23].

In the analysis of the relationship between different variables with dying from COVID-19 was found that age group, hospitalization, pneumonia, diabetes, COPD, asthma, immunosuppression, hypertension, chronic kidney disease, obesity, and smoking are related to death from COVID-19 (P < 0.05) (Table 2). Nevertheless, these relationships are lost when analyzing the logistic regression model that included all the variables associated with death from COVID-19.

The age group of 40-49 years shows an effect on dying from COVID-19 (OR =
4.97, 95% CI 1.61 -15.36). The age group from 40 to 49 years had the higher CFR, 3.74%.



202	The difference in days between the onset of symptoms and the date of registry in the
203	NESS/DGE system is at the limit of statistical significance ( $OR = 1.04, 95\%$ CI 1.00-1.09).
204	Pneumonia is the one variable with the highest effect on dying (OR = $8.68$ , $95\%$ CI 5.64 -
205	13.37). COPD, asthma, and smoking show ORs close to 1 (Table 3), which indicates a
206	slight effect.
207	Pneumonia showed the highest OR on death from COVID-19 (Table 3), consistent
208	with previous reports concerning children and adults, where the principal cause of death
209	was pneumonia.
210	The underlying pathologies that aggravate COVID-19 in the general population
211	seem to have minor effects on the severity of COVID-19 in pregnant women.
212	Pregnant women have been considered a risk group for COVID-19. In the database
213	analyzed, the co-morbidities did not play a statistically significant role in death while
214	integrating them in a multivariable logistic regression model, except for COPD and asthma
215	Also, health care workers must monitor the development of pneumonia because it is
216	significantly related to death. A substantial limitation of this study is the absence of data
217	about gestational age. This variable could play a confounding role in mortality. It is worth
218	noting that some deaths occurred among pregnant women with ambulatory care. It should
219	be addressed in further research. Due to the limitations of the database, it was not possible
220	in this study.

# 221 Conclusion

As in the general population, older age and pneumonia relate to death. The comorbidities had a low prevalence among pregnant women. Since the reproductive age

12



- usually ends at 50, pregnant women have two protective factors for COVID-19 detected in
- the literature: being young and woman. They have been two inherent confounding factors
- in this study.

### 227 **References**

- 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan,
- 229 China: the mistery and miracle. J Med Viral (2020) 92(94):401-402. Doi:
- 230 http://doi.org/10.1002/jmv.25678
- 231 2. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin,
- transmission, and characteristics of human coronaviruses J Adv Res (2020) 24: 91–98.
- 233 Doi: https://doi.org/10.1016/j.jare.2020.03.005
- 3. Secretariat of Health. Novel Coronavirus in the World: COVID-19. Technical
- 235 Communicate Daily (2021).
- 236 (https://www.gob.mx/cms/uploads/attachment/file/678900/Comunicado\_Tecnico\_Diario
- 237 \_COVID-19\_2021.11.01.pdf) [Accessed November 3, 2021]
- 4. Salem D, Katranji F, Bakdash T. COVID-19 infection in pregnant women; Review of
- maternal and fetal outcomes. International Journal of Gynecology & Obstetrics (2020)
- 240 152(3):291-298. Doi: https://doi.org/10.1002/ijgo.13533
- 5. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA et
- al. Pregnancy and COVID-19. Physiol Rev (2021) 101(1):303-318. doi:
- 243 https://doi.org/10.1152/physrev.00024.2020



- 6. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and
- neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a
- restrospective, single centre, descriptive study. Lancet Infec Dis (2020) 20(5): 559-564.
- 247 Doi: https://doi.org/10.1016/S1473-3099(20)30176-6
- 248 7. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and
- inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Nat
- 250 Sci Rev (2020) 7:998-1002. doi: https://doi.org/10.1093/nsr/nwaa041.
- 8. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of
- successful pregnancy. Hum Reprod Update (2003) 9:347-357. Doi:
- https://doi.org/10.1093/humupd/dmg026
- 9. Brandstadter JD, Yang Y. Natural killer cell responses to viral infection . J Innate Immun
- 255 (2011) 3:274-279. Doi: https://doi.org/10.1159/000324176
- 10. Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and
- 257 maintenance of pregnancy: is progesterone nature's immunosuppressant? Ann N Y
- 258 Acad Sci (1977) 286 (1 Biochemical A): 384-397. Doi:
- 259 https://doi.org/10.1111/j.1749-6632.1977.tb29431.x.
- 260 11. Young BC, Stanic AK, Panda B, Rueda BR, Panda A. Longitudinal expression of Toll-
- 261 like receptor son dendritic cells in uncomplicated pregnancy and postpartum. Am J
- 262 Obstet Gynecol (2014) 210:445.e1-445.e6. Doi:
- 263 https://doi.org/10.1016/j.ajog.2013.11.037
- 12. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med (2005)
- 265 33(Suppl):S390-S397. Doi: https://doi.org/10.1097/01.CCM.0000182483.24836.66



- 13. Di Renzo GC, Giardina I. Coronavirus disease 2019 in pregnancy consider
- thromboembolic disorders and thromboprophylaxis. Am J Obstet Gynecol (2020)
- 268 223(1):135. Doi: https://doi.org/10.1016/j.ajog.2020.04.017 2020.
- 269 14. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics
- and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2
- infection in UK: national population-based cohort study. BMJ (2020) 369:m2107. Doi:
- 272 https://doi.org/10.1136/bmj.m2107
- 273 15. Lopez-Rodriguez G, Galvan M, Galvan-Valencia O. Comorbidities associated with
- maternal mortality from COVID-19 in Mexico. Gac. Med. Mex 2021; 157 (6): 618-
- 275 622. Doi: https://doi.org/10.24875/gmm.21000221
- 16. General Directorate of Epidemiology. Sub-secretary of Prevention and Promotion of
- Health. Historical open databases (March 31, 2021).
- https://www.gob.mx/cms/uploads/attachment/file/673724/Datos\_abiertos\_hist\_ricos\_2
- 279 021.pdf) [Accesed November 1, 2021]
- 280 17. General Directorate of Epidemiology. Secretary of Health. Updating of the operational
- definition of a suspected case of viral respiratory disease (August 24, 2020).
- https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado\_Oficial\_DOC\_
- sospechoso\_ERV\_240820.pdf. [Accessed November 1, 2021]
- 18. Padilla-Raygoza N, Sandoval-Salazar C, Díaz-Becerril LA, Beltrán-Campos V, Díaz-
- 285 Martínez DA, Navarro-Olivos E, et al. Update of the Evolution of SARS-CoV-2
- Infection,COVID-19, and Mortality in Mexico Until May 15, 2020: An Ecological



- 287 Study. International Journal of TROPICAL DISEASE & Health (2020) 41(5): 36-45.
- 288 Doi: https://doi.org/10.9734/IJTDH/2020/v41i530277
- 289 19. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and
- intrauterine vertical transmission potential of COVID-19infection in nine pregnant
- women: a retrospective review of medical records. Lancet (2020) 395:809-815. Doi:
- 292 https://doi.org/10.1016/S0140-6736(20)30360-3.
- 20. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 (COVID-19 in
- pregnant women : A report based on 116 cases . Am J Obstet Gynecol (2020)
- 295 223(1):111.e1-111.e14. Doi: https://doi.org/10.1016/j.ajog.2020.04.014
- 296 21. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and
- neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a
- retrospective, single-centre, descriptive study. Lancet Infect Dis (2020) 20:559-564.
- 299 Doi: https://doi.org/10.1016/S1473-3099(20)30176-6.
- 22. Takemoto ML, Menezes MO, Anfreucci CB, Nakamura-Pereira M, Armorim MMR,
- 301 Katz L, et al. The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting.
- 302 Int J Gynaecol Obstet (2020) 1(1):154-156. Doi: https://doi.org/10.1002/ijgo.13300
- 303 22. Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J, Sokołowska M, Kwiatkowski S,
- 304 Torbé A. COVID-19 and pregnancy-where are we now? A review. J Perinat Ned
- 305 (2020) 48(5):428-434. Doi: http://doi.org/10.1515/jpm.2020.0132

### **306 Data Availability Statement**



- 307 The datasets analyzed for this study can be found in the Open Science Framework
- 308 Padilla-Raygoza N. COVID-19 in Mexican pregnant [Internet]. OSF; 2021. Available
- 309 from: https://osf.io/b8hyw/